Onychomycosis Treatment Market Size to Reach US$ 4.3 Billion by 2028, at a CAGR of 5.37%

According to the latest report by IMARC Group, titled "Onychomycosis Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028," The global onychomycosis treatment market size reached US$ 3.1 Billion in 2022. Looking forward, the market expected to reach US$ 4.3 Billion by 2028, exhibiting a growth rate (CAGR) of 5.37% during 2023-2028.

Onychomycosis represents a fungal infection that usually occurs in the fingernails and toenails that can lead to discomfort, chronic pain, and disfigurement. It is caused by several organisms, such as dermatophytes, yeasts, non-dermatophyte molds, etc. Some of the common types of onychomycosis include proximal subungual, white superficial, and distal subungual. It is characterized by symptoms, including foul smell, distortion in the shape of nails, whitish to yellow-brown discoloration, brittle, ragged, and crumbly texture of the nails, etc. Onychomycosis is generally diagnosed via potassium, oxygen, and hydrogen (KOH) examination and histopathological examinations of nail clippings and nail biopsies. It is treated through drugs, laser therapy, photodynamic therapies, etc.

Request Free Sample Report: https://www.imarcgroup.com/onychomycosis-treatment-market/requestsample

Global Onychomycosis Treatment Market Trends and Drivers:

The growing prevalence of chronic medical ailments, such as human immunodeficiency virus (HIV), diabetes, peripheral artery disease (PAD), etc., is primarily driving the onychomycosis treatment market. Additionally, the expanding geriatric population who are highly prone to circulatory disorders and weakened immune systems is further catalyzing the market growth. Besides this, the rising incidences of onychomycosis among millennials, owing to the increased exposure to public swimming pools and the widespread adoption of tight, contaminated, or soiled clothes, shoes, and socks, are acting as significant growth-inducing factors. Moreover, the escalating demand for topical nail lacquers and ointments to maintain nail hygiene is positively influencing the global market. Apart from this, the introduction of water-soluble antifungal treatment solutions that can be administered orally is also bolstering the market growth. Furthermore, they help in preventing secondary bacterial infections and prevent the growth of fungus, which is anticipated to fuel the onychomycosis treatment market over the forecasted period.

Onychomycosis Treatment Market 2023-2028 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Bausch Health Companies Inc.
Cipla Limited
Reddy's Laboratories
Galderma SA
GlaxoSmithKline PLC
Kaken Pharmaceutical Co. Ltd
Lumenis Ltd
Moberg Pharma AB
Novartis AG
fizer Inc.
The OTC Lab B.V.

The report has segmented the market on the basis on region, disease type, treatment type, drug class and distribution channel.

Breakup by Disease Type:
Distal Subungual Onychomycosis
Proximal Subungual Onychomycosis
White Superficial Onychomycosis
Candidal Onychomycosis
Others

Breakup by Treatment Type:
Laser Therapy
Photodynamic Therapy
Drug Treatment

Breakup by Drug Class:
Allylamine
Azole
Griseofulvin
Others

Breakup by Distribution Channel:
Hospitals and Clinics
Online Stores
Retail Pharmacies
Others

Breakup by Region:
North America
Asia-Pacific
Europe
Latin America
Middle East and Africa

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/onychomycosis-treatment-market

Key highlights of the report:

Market Performance (2017-2022)
Market Outlook (2023-2028)
Porter's Five Forces Analysis
Market Drivers and Success Factors
SWOT Analysis
Value Chain
Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Browse Top Trending Reports:

https://www.openpr.com/news/3019817/fleet-management-system-market-size-to-hit-us-43-1-billion

https://www.openpr.com/news/3019860/smart-packaging-market-size-to-hit-us-49-8-billion-by-2028-cagr

https://www.openpr.com/news/3019954/smart-textiles-market-size-to-hit-us-15-9-billion-by-2028-cagr

https://www.openpr.com/news/3019998/data-center-fabric-market-size-to-hit-us-102-4-billion-by-2028

https://www.openpr.com/news/3020030/sukuk-market-size-to-hit-us-2-276-billion-by-2028-cagr-of-16-2

https://www.openpr.com/news/3020067/essential-oils-market-size-to-hit-us-18-8-billion-by-2028-cagr

https://www.openpr.com/news/3020119/virtual-production-market-2023-2028-share-size-growth-top

Contact Us:

IMARC Group
Email: sales@imarcgroup.com
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Website: https://www.imarcgroup.com/
Follow us on Twitter: @imarcglobal
Linkedin: https://www.linkedin.com/company/imarc-group

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

This release was published on openPR.